VELICO MEDICAL, INC.

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0001, 0005, 0008, 0009, EXTEND THE PERIOD OF PERFORMANCE THROUGH JUNE 30, 2026, FOR CLINS 0004 AND 0005; AND CLIN 0009 THROUGH FEBRUARY 28, 2026, DUE TO DELAY IN COMPLETION

BLOOD PLASMA SPRAY DRYING SYSTEM

THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FUND OPTION 8/CLIN0009, PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0001, 0002, 0003, 0004, 0005, UPDATE SOW DATED 12/26/23, AND EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 THROUGH DECEMBER 29, 2024, C

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.